ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR-T Cell Engineering.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lipid nanoparticles (LNPs) are proposed as an attractive non-viral alternative for mRNA-based CAR-T cell engineering. However, the impact of the LNP charge and the composition of the transfection medium remain to be fully explored. Here, charge-neutral C12-200 LNPs and cationic DOTAP(C12-200) LNPs were compared for ex vivo transfection of activated primary human T cells. C12-200 LNPs achieved efficient transfection with high cell viability in serum-free medium supplemented with apolipoprotein E. Transfection efficiency correlated with low-density lipoprotein receptor expression following T cell activation, suggesting receptor-mediated uptake. In contrast, cationic LNPs demonstrated superior mRNA expression independent of medium composition or T cell activation state, albeit with reduced cytocompatibility. Both LNPs efficiently delivered anti-CD20 nanoCAR mRNA into primary T cells, enabling potent cytotoxicity against CD20
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.